Back to Home

Highlights From The Most Recent Investors Webinar

March 4, 2025

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon
View as PDF

Highlights From The Most Recent Investors Webinar

June 9, 2025


THIS OPPORTUNITY CLOSES MARCH 6, 2025


‍

On February 18, RegenMed’s Co-Founder and Chief Executive Officer Michael P. Tierney, and its Chief Technology and Information Officer, Dolph Courchaine, were interviewed during the final Investors Webinar prior to the conclusion of this investment round.  Key segments can be found on the Company’s YouTube channel, with links below.  The entire playlist is here.

RegenMed’s leadership and employees extend their deep gratitude to all fellow shareholders for their support.  The Company looks forward to an exciting 2025 with continued acceleration of its growth in the fundamentally important world of healthcare data and value-based medicine.

  • Understanding The Company
 
  • Technology and Innovation
  • Challenges In Healthcare
 
  • Future Plans and Market Expansion
  • Data Ownership and Licensing
 
  • Involving Doctors In Gathering the Most Valuable Data
  • Revenue Generation and Business Model
 
  • Value Proposition. Applicability Outside The United States
  • Four Revenue Lines
 
  • The YouTube Comparison
  • Further Discussion On The Importance Of Data Ownership
 
  • Dolph Courchaine, CTIO: Three Game-Changing Benefits
  • Circles: What Is In It For Physicians
  

THIS OPPORTUNITY CLOSES MARCH 6, 2025


Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon

Highlights From The Most Recent Investors Webinar

March 4, 2025


THIS OPPORTUNITY CLOSES MARCH 6, 2025


‍

On February 18, RegenMed’s Co-Founder and Chief Executive Officer Michael P. Tierney, and its Chief Technology and Information Officer, Dolph Courchaine, were interviewed during the final Investors Webinar prior to the conclusion of this investment round.  Key segments can be found on the Company’s YouTube channel, with links below.  The entire playlist is here.

RegenMed’s leadership and employees extend their deep gratitude to all fellow shareholders for their support.  The Company looks forward to an exciting 2025 with continued acceleration of its growth in the fundamentally important world of healthcare data and value-based medicine.

  • Understanding The Company
 
  • Technology and Innovation
  • Challenges In Healthcare
 
  • Future Plans and Market Expansion
  • Data Ownership and Licensing
 
  • Involving Doctors In Gathering the Most Valuable Data
  • Revenue Generation and Business Model
 
  • Value Proposition. Applicability Outside The United States
  • Four Revenue Lines
 
  • The YouTube Comparison
  • Further Discussion On The Importance Of Data Ownership
 
  • Dolph Courchaine, CTIO: Three Game-Changing Benefits
  • Circles: What Is In It For Physicians
  

THIS OPPORTUNITY CLOSES MARCH 6, 2025


𝘛𝘩𝘪𝘴 𝘙𝘦𝘨 𝘊𝘍 𝘰𝘧𝘧𝘦𝘳𝘪𝘯𝘨 𝘪𝘴 𝘮𝘢𝘥𝘦 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘚𝘵𝘢𝘳𝘵𝘌𝘯𝘨𝘪𝘯𝘦 𝘗𝘳𝘪𝘮𝘢𝘳𝘺 𝘓𝘓𝘊, 𝘮𝘦𝘮𝘣𝘦𝘳 𝘍𝘐𝘕𝘙𝘈/𝘚𝘐𝘗𝘊. 𝘛𝘩𝘪𝘴 𝘪𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵 𝘪𝘴 𝘴𝘱𝘦𝘤𝘶𝘭𝘢𝘵𝘪𝘷𝘦, 𝘪𝘭𝘭𝘪𝘲𝘶𝘪𝘥, 𝘢𝘯𝘥 𝘪𝘯𝘷𝘰𝘭𝘷𝘦𝘴 𝘢 𝘩𝘪𝘨𝘩 𝘥𝘦𝘨𝘳𝘦𝘦 𝘰𝘧 𝘳𝘪𝘴𝘬, 𝘪𝘯𝘤𝘭𝘶𝘥𝘪𝘯𝘨 𝘵𝘩𝘦 𝘱𝘰𝘴𝘴𝘪𝘣𝘭𝘦 𝘭𝘰𝘴𝘴 𝘰𝘧 𝘺𝘰𝘶𝘳 𝘦𝘯𝘵𝘪𝘳𝘦 𝘪𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵. 𝘛𝘩𝘪𝘴 𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘢𝘵𝘪𝘰𝘯 𝘮𝘢𝘺 𝘤𝘰𝘯𝘵𝘢𝘪𝘯 𝘧𝘰𝘳𝘸𝘢𝘳𝘥-𝘭𝘰𝘰𝘬𝘪𝘯𝘨 𝘴𝘵𝘢𝘵𝘦𝘮𝘦𝘯𝘵𝘴 𝘣𝘢𝘴𝘦𝘥 𝘰𝘯 𝘤𝘶𝘳𝘳𝘦𝘯𝘵 𝘦𝘹𝘱𝘦𝘤𝘵𝘢𝘵𝘪𝘰𝘯𝘴. 𝘈𝘤𝘵𝘶𝘢𝘭 𝘳𝘦𝘴𝘶𝘭𝘵𝘴 𝘤𝘰𝘶𝘭𝘥 𝘥𝘪𝘧𝘧𝘦𝘳 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵𝘭𝘺 𝘥𝘶𝘦 𝘵𝘰 𝘷𝘢𝘳𝘪𝘰𝘶𝘴 𝘳𝘪𝘴𝘬𝘴 𝘢𝘯𝘥 𝘶𝘯𝘤𝘦𝘳𝘵𝘢𝘪𝘯𝘵𝘪𝘦𝘴.

‍

‍

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon

Read The Latest

June 26, 2025

Invest in the Future: Webinar with Our CEO and Co-Founder

Discover the incredible growth potential of our company! Join our CEO and Co-Founder for insights into our $100B market opportunity, ongoing market traction, and future projections.

June 4, 2025

Advantages Of Circles Over "Big Data" RWE

Discover how Circles transform Big Data RWE by providing transparent, high-integrity insights directly from trusted sources. Say goodbye to fragmented, costly data and unlock meaningful, clinically relevant information while empowering physicians.

June 3, 2025

Peptides In Modern Medicine: Establishing Safety and Efficacy

Peptides are revolutionizing clinical diagnosis and treatment with their high selectivity and favorable side effect profiles. Here are some key insights:

RegenMed LLC Logo
Scroll Up Arrow

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.

Forward looking statements were included here that the Company believes to be accurate given the current information. They involve known and unknown risks, uncertainties and other important factors which if changed may affect the outcome(s).

DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 4000 Eagle Point Corporate Drive, Suite 950, Birmingham, AL 35242., is the Intermediary for this offering and is not an affiliate of or connected with the Issuer.  Please check our background on FINRA's BrokerCheck.
DealMaker Securities LLC does not make investment recommendations.
DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer.
DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor's documentation for this investment.
DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing.
DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself.

Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

Copyright © 2025. RegenMed, Inc. All rights reserved.